Evidence map›Paper›PMID 38495296›Full record

ArticleCytotechnology2024

Selective elimination of tumorigenic cells from mixed culture of normal and tumorigenic cells using hybrid liposomes aimed at realizing of cell therapy.

Riko Jinno, Moe Tanaka, Yuji Komizu, Yoko Matsumoto, Taku Matsushita, Seiichi Ishida

Open access · hybridAbstract read
In one paragraph

Article in Cytotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Riko JinnoDivision of Applied Life Science, Graduate School of Engineering, Sojo University, Kumamoto, Japan.
Moe TanakaDivision of Applied Life Science, Graduate School of Engineering, Sojo University, Kumamoto, Japan.
Yuji KomizuDivision of Applied Life Science, Graduate School of Engineering, Sojo University, Kumamoto, Japan.
Yoko MatsumotoDivision of Applied Life Science, Graduate School of Engineering, Sojo University, Kumamoto, Japan.
Taku MatsushitaDivision of Applied Life Science, Graduate School of Engineering, Sojo University, Kumamoto, Japan.
Seiichi IshidaDivision of Applied Life Science, Graduate School of Engineering, Sojo University, Kumamoto, Japan.
Sojo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While induced pluripotent stem (iPS) cells are expected to be a cell source for regenerative medicine, they also have tumorigenic properties owing to their proliferative potential. During the manufacturing of regenerative medicine products, undifferentiated iPS cells and malignant transformed cells may be mixed in the cell culture population. Therefore, it is essential to eliminate tumorigenic cells selectively. In this study, a mixed culture of normal human fetal hepatocytes (Hc cells) and human hepatocellular carcinoma cells (HuH-7 cells) was used as a cell population model to be used as regenerative medicine products, and the selective elimination of HuH-7 cells by hybrid liposomes (HL) was analyzed. HL tended to fuse and accumulate more in HuH-7 cells due to larger fluidity of plasma membrane for HuH-7 cells than that for Hc cells. In a mixed culture of Hc and HuH-7 cells, HL selectively eliminated HuH-7 cells while allowing Hc cells to remain viable. In addition, HL treatment for the mixed culture of Hc and HuH-7 cells suppressed the tumorigenicity of HuH-7 cells. Therefore, HL selectively fused and accumulated in tumorigenic cells in a mixed cell culture of normal and tumorigenic cells, and eliminated tumorigenic cells while allowing normal cells to remain viable. The results of this study suggest the potential of HL in eliminating tumorigenic cells during the manufacturing of regenerative medicine products. Thus, HL could be expected to contribute to the development of safe regenerative medical products. Supplementary Information: The online version contains supplementary material available at 10.1007/s10616-023-00613-y.

Indexed as

Hybrid liposomesRegenerative medicineSafetySelective eliminationTumorigenic cells

Identifiers

PMID38495296
PMCPMC10940552
OpenAlexW4391782381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.